Alfred T Welzel
Overview
Explore the profile of Alfred T Welzel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phay M, Welzel A, Williams A, McWilliams-Koeppen H, Blinder V, OMalley T, et al.
PLoS One
. 2015 Sep;
10(9):e0137344.
PMID: 26367058
Amyloid-reactive IgGs isolated from pooled blood of normal individuals (pAbs) have demonstrated clinical utility for amyloid diseases by in vivo targeting and clearing amyloidogenic proteins and peptides. We now report...
2.
Welzel A, Maggio J, Shankar G, Walker D, Ostaszewski B, Li S, et al.
Biochemistry
. 2014 May;
53(24):3908-21.
PMID: 24840308
Evidence for a central role of amyloid β-protein (Aβ) in the genesis of Alzheimer’s disease (AD) has led to advanced human trials of Aβ-lowering agents. The “amyloid hypothesis” of AD...
3.
Welzel A, Williams A, McWilliams-Koeppen H, Acero L, Weber A, Blinder V, et al.
PLoS One
. 2012 Dec;
7(11):e50317.
PMID: 23209707
Soluble non-fibrillar assemblies of amyloid-beta (Aβ) and aggregated tau protein are the proximate synaptotoxic species associated with Alzheimer's disease (AD). Anti-Aβ immunotherapy is a promising and advanced therapeutic strategy, but...
4.
Shankar G, Welzel A, McDonald J, Selkoe D, Walsh D
Methods Mol Biol
. 2010 Oct;
670:33-44.
PMID: 20967581
Recent data suggest that soluble, non-fibrillar assemblies of the amyloid β-protein (Aβ) may mediate the synaptic deficits that characterize the early stages of Alzheimer's disease. Consequently, much effort has been...
5.
Mc Donald J, Savva G, Brayne C, Welzel A, Forster G, Shankar G, et al.
Brain
. 2010 Apr;
133(Pt 5):1328-41.
PMID: 20403962
The molecular pathways leading to Alzheimer-type dementia are not well understood, but the amyloid beta-protein is believed to be centrally involved. The quantity of amyloid beta-protein containing plaques does not...
6.
Reed M, Hofmeister J, Jungbauer L, Welzel A, Yu C, Sherman M, et al.
Neurobiol Aging
. 2009 Dec;
32(10):1784-94.
PMID: 20031278
Soluble forms of amyloid-β peptide (Aβ) are a molecular focus in Alzheimer's disease research. Soluble Aβ dimers (≈8 kDa), trimers (≈12 kDa), tetramers (≈16 kDa) and Aβ*56 (≈56 kDa) have...
7.
Kukar T, Ladd T, Bann M, Fraering P, Narlawar R, Maharvi G, et al.
Nature
. 2008 Jun;
453(7197):925-9.
PMID: 18548070
Selective lowering of Abeta42 levels (the 42-residue isoform of the amyloid-beta peptide) with small-molecule gamma-secretase modulators (GSMs), such as some non-steroidal anti-inflammatory drugs, is a promising therapeutic approach for Alzheimer's...
8.
Klyubin I, Betts V, Welzel A, Blennow K, Zetterberg H, Wallin A, et al.
J Neurosci
. 2008 Apr;
28(16):4231-7.
PMID: 18417702
The current development of immunotherapy for Alzheimer's disease is based on the assumption that human-derived amyloid beta protein (Abeta) can be targeted in a similar manner to animal cell-derived or...